New Protocols (18*)
Anal Carcinoma
- Retifanlimab 500, Anal Carcinoma PID 2867 V1.0 (2025-05-20)
- Carboplatin 5 / Paclitaxel 80 / Retifanlimab 500, Anal Carcinoma PID 2868 V1.0 (2025-05-20)
- Carboplatin 5 / Paclitaxel 80 / Retifanlimab 500 - Retifanlimab 500, Anal Carcinoma, maintenance PID 2869 V1.0 (2025-05-20)
Colon Cancer
- IROX - Irinotecan 200 / Oxaliplatin 85, Colorectal Carcinoma PID 2909 V1.0 (2025-05-20)
- Modified FOLFOX-6 - Cetuximab 500 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma PID 2907 V1.0 (2025-05-17)
- FOLFOX-6 - Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400 / Cetuximab 500 / Encorafenib 300, Colorectal Carcinoma PID 2910 V1.0 (2025-05-17)
- FOLFIRI - Cetuximab 500 / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma PID 2912 V1.0 (2025-05-17)
- Cetuximab 500 / Irinotecan 180, Colorectal Carcinoma PID 2908 V1.0 (2025-05-16)
- Encorafenib 300 / Cetuximab 500, Colorectal Carcinoma PID 2911 V1.0 (2025-05-16)
Lung Carcinoma, Small Cell
- Tislelizumab 200 / Cisplatin 75 / Etoposid 100, kleinzelliges Lungenkarzinom, Zyklus 1-4 PID 2914 V1.0 (2025-05-20)
- Tislelizumab 200 / Carboplatin 5 / Etoposid 100, kleinzelliges Lungenkarzinom, Zyklus 1-4 PID 2915 V1.0 (2025-05-20)
- Tislelizumab 200, kleinzelliges Lungenkarzinom, Zyklus 5+ PID 2916 V1.0 (2025-05-20)
Lung Carcinoma, Non-Small Cell
- Lazertinib 240 / Amivantamab 1600, Non-Small Cell Lung Cancer, Cycle 1 PID 2902 V1.0 (2025-05-19)
- Lazertinib 240 / Amivantamab 1600, Non-Small Cell Lung Cancer, Cycle 2+ PID 2903 V1.0 (2025-05-19)
- Lazertinib 240 / Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 1 PID 2904 V1.0 (2025-05-19)
- Lazertinib 240 / Amivantamab 2240, Non-Small Cell Lung Cancer, Cycle 2+ PID 2905 V1.0 (2025-05-19)
NHL, B-Cell Type, Diffuse Large Cell
Prostate Cancer
Updated Protocols (1*)
Lung Carcinoma, Small Cell
- Cisplatin 75 / Etoposide 100, Small Cell Lung Carcinoma PID 2266 V1.1 (2025-05-20)V1.1: Volumengabe an Tag 2 und 3 angepasst V1.0: Cato Test erfolgt. V0.1: Reihenfolge der Substanzen nach Primärliteratur, abweichend von Sundstrom.
Protocols in Revision
Multiple Myeloma
- Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Isatuximab 10, multiple myeloma, induction, IB, cycle 1 PID 41 V1.2
- Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Isatuximab 10, multiple myeloma, induction, IB, cycle 2-3 PID 42 V1.2